Floatz logo

Cetuximab

Cervical Small Cell Carcinoma

Gynecologic Oncology Groupmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cervical Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 2B
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
FERUMOXTRAN 10
National Cancer Institute (NCI)
Phase 1/2CCC
1-(4,4-BIS(P-FLUOROPHENYL)BUTYL)-4-(4-CHLORO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-4-PIPERIDINOL
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2CCC
Axalimogene Filolisbac
Advaxis, Inc.
Phase 1CC

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
BRAF V600E-mutated /MSS Metastatic Colorectal CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →